These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7046953)

  • 21. In vitro inhibition of the classical pathway of human complement by polymyxin B.
    Asghar SS; Boot T; van der Helm HJ
    Biochem Pharmacol; 1987 Sep; 36(18):2927-30. PubMed ID: 2820426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic differences between migration inhibitory factor (MIF) and IFN-gamma for macrophage activation. MIF and IFN-gamma synergize with lipid A to mediate migration inhibition but only IFN-gamma induces production of TNF-alpha and nitric oxide.
    Herriott MJ; Jiang H; Stewart CA; Fast DJ; Leu RW
    J Immunol; 1993 May; 150(10):4524-31. PubMed ID: 7683323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of macrophage migration by plasma factor(s) from patients with neoplasms and normal individuals.
    Bice DE; Gruwell D; Salvaggio J
    J Reticuloendothel Soc; 1976 May; 19(5):281-9. PubMed ID: 775085
    [No Abstract]   [Full Text] [Related]  

  • 24. Studies of assay conditions for macrophage migration from an agarose droplet.
    Fahlbusch B; Dornberger G
    Acta Biol Med Ger; 1979; 38(10):1453-60. PubMed ID: 44954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of migration inhibitory factor activity by plasma esterase inhibitors.
    Remold HG; Rosenberg RD
    J Biol Chem; 1975 Aug; 250(16):6608-13. PubMed ID: 1099092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inability to block the activity of guinea pig migration inhibitory factor with di-isopropyl phosphorofluoridate.
    David JR; Becker EL
    Eur J Immunol; 1974 Apr; 4(4):287-9. PubMed ID: 4604594
    [No Abstract]   [Full Text] [Related]  

  • 27. Salt-sensitivity of complement (C)-consumption induced by anticomplementary antigens and antigen/antibody complexes.
    Gancevici G; Popescu C; Toporan M
    Arch Roum Pathol Exp Microbiol; 1982; 41(3):239-50. PubMed ID: 6818928
    [No Abstract]   [Full Text] [Related]  

  • 28. Refractoriness to migration inhibitory factor of macrophages of LPS nonresponder mouse strains.
    Tagliabue A; McCoy JL; Herberman RB
    J Immunol; 1978 Oct; 121(4):1223-6. PubMed ID: 359704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. II. Complement activating property of the lipopolysaccharide portion and the inhibition by polymyxin B.
    Inada K
    Jpn J Exp Med; 1980 Apr; 50(2):107-15. PubMed ID: 6256561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A macrophage surface component related to fibronectin is involved in the response to migration inhibitory factor.
    Remold HG; Shaw JE; David JR
    Cell Immunol; 1981 Feb; 58(1):175-87. PubMed ID: 7013990
    [No Abstract]   [Full Text] [Related]  

  • 31. Potentiation of the macrophage response to migration inhibition factor from fetal calf serum by blood group substances with human H activity.
    Fox RA; MacSween JM; McGuire RL
    Scand J Immunol; 1976; 5(8):941-7. PubMed ID: 792986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human recombinant migration inhibitory factor activates human macrophages to kill Leishmania donovani.
    Weiser WY; Pozzi LM; David JR
    J Immunol; 1991 Sep; 147(6):2006-11. PubMed ID: 1909737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of macrophage migration by a soluble factor from lymphocytes stimulated with PHA or ALS.
    Lamelin JP; Vassalli P
    Nature; 1971 Feb; 229(5284):426-8. PubMed ID: 4926999
    [No Abstract]   [Full Text] [Related]  

  • 34. Increased responsiveness to macrophage-activating factor (MAF) after alteration of macrophage membranes.
    Piessens WF; Remold HG; David JR
    J Immunol; 1977 Jun; 118(6):2078-82. PubMed ID: 325137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage migration inhibition factor: interactions with calcium, magnesium, and cyclic AMP.
    Block LH; Aloni B; Biemesderfer D; Kashgarian M; Bitensky MW
    J Immunol; 1978 Oct; 121(4):1416-21. PubMed ID: 212481
    [No Abstract]   [Full Text] [Related]  

  • 36. An ELISA method for quantitation of macrophage migration from agarose microdroplets.
    Peck R
    J Immunol Methods; 1983 Nov; 64(1-2):179-87. PubMed ID: 6358361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Demonstration of a complement-dependent migration inhibitory activity in normal guinea pig serum.
    Sandru G; Veraguth P
    Allergy; 1980 Jan; 35(1):37-43. PubMed ID: 6989284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the interaction of macrophage inhibitory factor (MIF) with the macrophage.
    Remold HG
    Clin Immunol Immunopathol; 1975 Nov; 4(4):573-6. PubMed ID: 1106928
    [No Abstract]   [Full Text] [Related]  

  • 39. Identity of specific macrophage-active human lymphokines.
    Block LH; Jaksche H; Bamberger S; Ruhenstroth-Bauer G
    Lancet; 1978 Apr; 1(8066):718-9. PubMed ID: 76257
    [No Abstract]   [Full Text] [Related]  

  • 40. Possible role of macrophage glycolipids as receptors for migration inhibitory factor (MIF).
    Higgins TJ; Sabatino AP; Remold HG; David JR
    J Immunol; 1978 Sep; 121(3):880-6. PubMed ID: 357658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.